A detailed history of Squarepoint Ops LLC transactions in Altimmune, Inc. stock. As of the latest transaction made, Squarepoint Ops LLC holds 61,688 shares of ALT stock, worth $496,588. This represents 0.0% of its overall portfolio holdings.

Number of Shares
61,688
Holding current value
$496,588
% of portfolio
0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.5 - $8.1 $339,284 - $499,672
61,688 New
61,688 $378,000
Q1 2024

May 15, 2024

SELL
$8.22 - $13.81 $818,670 - $1.38 Million
-99,595 Reduced 88.31%
13,178 $134,000
Q4 2023

Feb 14, 2024

SELL
$2.14 - $11.62 $58,075 - $315,343
-27,138 Reduced 19.4%
112,773 $1.27 Million
Q2 2023

Aug 14, 2023

SELL
$3.45 - $5.97 $256,517 - $443,887
-74,353 Reduced 34.7%
139,911 $493,000
Q1 2023

May 15, 2023

BUY
$4.19 - $16.83 $897,766 - $3.61 Million
214,264 New
214,264 $904,000
Q2 2022

Aug 15, 2022

SELL
$3.94 - $11.77 $261,986 - $782,634
-66,494 Reduced 70.27%
28,133 $329,000
Q1 2022

May 16, 2022

BUY
$5.9 - $9.45 $473,451 - $758,324
80,246 Added 558.0%
94,627 $576,000
Q4 2021

Feb 14, 2022

SELL
$8.69 - $12.48 $401,712 - $576,912
-46,227 Reduced 76.27%
14,381 $132,000
Q3 2021

Nov 15, 2021

BUY
$8.43 - $16.81 $423,658 - $844,803
50,256 Added 485.47%
60,608 $685,000
Q2 2021

Aug 16, 2021

BUY
$9.85 - $16.46 $101,967 - $170,393
10,352 New
10,352 $102,000
Q4 2020

Feb 16, 2021

SELL
$7.84 - $14.22 $160,147 - $290,471
-20,427 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$9.93 - $33.26 $202,840 - $679,402
20,427 New
20,427 $270,000
Q4 2019

Feb 14, 2020

SELL
$1.53 - $2.15 $17,209 - $24,183
-11,248 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$1.95 - $2.66 $20,030 - $27,323
-10,272 Reduced 47.73%
11,248 $22,000
Q2 2019

Aug 14, 2019

SELL
$2.19 - $3.4 $27,037 - $41,976
-12,346 Reduced 36.46%
21,520 $51,000
Q1 2019

May 15, 2019

BUY
$2.54 - $4.54 $86,019 - $153,751
33,866 New
33,866 $98,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $395M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.